Yanjun Liu

601 Western Huangpu Avenue
Guangzhou, 510632, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells.

System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: December 25, 2022

PPFIA1-targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration.

PPFIA1-targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration.

Journal: Molecular therapy. Nucleic acids

Published: December 20, 2022

Single-cell resolution reveals RalA GTPase expanding hematopoietic stem cells and facilitating of BCR-ABL1-driven leukemogenesis in a CRISPR/Cas9 gene editing mouse model.

Single-cell resolution reveals RalA GTPase expanding hematopoietic stem cells and facilitating of BCR-ABL1-driven leukemogenesis in a CRISPR/Cas9 gene editing mouse model.

Journal: International journal of biological sciences

Published: July 10, 2022

Targeting SOS1 overcomes imatinib resistance with BCR-ABL independence through uptake transporter SLC22A4 in CML.

Targeting SOS1 overcomes imatinib resistance with BCR-ABL independence through uptake transporter SLC22A4 in CML.

Journal: Molecular therapy oncolytics

Published: June 05, 2021

Discovery of the oncogenic MDM2, a direct binding target of berberine and a potential therapeutic, in multiple myeloma.

Discovery of the oncogenic MDM2, a direct binding target of berberine and a potential therapeutic, in multiple myeloma.

Journal: Functional & integrative genomics

Published: December 15, 2020

Identification of berberine as a novel drug for the treatment of multiple myeloma via targeting UHRF1.

Identification of berberine as a novel drug for the treatment of multiple myeloma via targeting UHRF1.

Journal: BMC biology

Published: September 16, 2019

Discovery of Berberine that Targetedly Induces Autophagic Degradation of both BCR-ABL and BCR-ABL T315I through Recruiting LRSAM1 for Overcoming Imatinib Resistance.

Discovery of Berberine that Targetedly Induces Autophagic Degradation of both BCR-ABL and BCR-ABL T315I through Recruiting LRSAM1 for Overcoming Imatinib Resistance.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 28, 2019

The role of phosphorylation of MLF2 at serine 24 in BCR-ABL leukemogenesis.

The role of phosphorylation of MLF2 at serine 24 in BCR-ABL leukemogenesis.

Journal: Cancer gene therapy

Published: July 20, 2019

The Identification of Long Non-coding RNA H19 Target and Its Function in Chronic Myeloid Leukemia.

The Identification of Long Non-coding RNA H19 Target and Its Function in Chronic Myeloid Leukemia.

Journal: Molecular therapy. Nucleic acids

Published: June 07, 2019

Discovery of the Oncogenic Parp1, a Target of bcr-abl and a Potential Therapeutic, in mir-181a/PPFIA1 Signaling Pathway.

Discovery of the Oncogenic Parp1, a Target of bcr-abl and a Potential Therapeutic, in mir-181a/PPFIA1 Signaling Pathway.

Journal: Molecular therapy. Nucleic acids

Published: April 01, 2018

Signal pathways, diseases, and functions associated with the miR-19a/92a cluster and the use of berberine to modulate the expression of this cluster in multiple myeloma cells.

Signal pathways, diseases, and functions associated with the miR-19a/92a cluster and the use of berberine to modulate the expression of this cluster in multiple myeloma cells.

Journal: Journal of biochemical and molecular toxicology

Published: December 04, 2017

Showing 1-11 of 11

Last Updated: 09/26/2026